Biogen | BIIB - Betriebsaufwand

Aktienkurs
184.38
Täglich Wechseln
-3.50 -1.86%
Monatlich
-2.54%
Jährlich
55.15%
Q2 Prognose
180.43




Betriebsaufwand Veränderung Datum
AbbVie USD 10.81B 13.45B 2025-12
Acadia Pharmaceuticals USD 266.6M 23.72M 2025-12
ALKERMES USD 326.44M 1.41B 2025-12
Amgen USD 5.9B 773M 2025-12
Bayer EUR 10.33B 126M 2025-12
Biogen USD 1.88B 81.4M 2025-09
BioMarin Pharmaceutical USD 676.18M 131.65M 2025-12
Bristol-Myers Squibb USD 8.3B 10.25B 2025-12
Eli Lilly USD 10.31B 1.09B 2025-12
Esperion Therapeutics USD 83.21M 14.06M 2025-12
Gilead Sciences USD 4.96B 707M 2025-12
Incyte USD 1.12B 3.53B 2025-12
Merck USD 10.16B 558M 2025-12
Moderna USD 1.54B 259M 2025-12
Neurocrine Biosciences USD 577.6M 22M 2025-12
Novartis USD 9.8B 61M 2025-12
Pfizer USD 12.91B 79.89B 2025-12
PTC Therapeutics USD 246.3M 38.78M 2025-12
Puma Biotechnology USD 49.26M 3.2M 2024-06
Regeneron Pharmaceuticals USD 2.99B 27.97B 2025-12
Sangamo BioSciences USD 33.87M 12.89M 2024-06
Sanofi EUR 9.31B 1.2B 2026-03
Sanofi EUR 10.71B 1.32B 2025-12
Sarepta Therapeutics USD 853.02M 390.78M 2025-12
Teva Pharmaceutical Industries USD 4.22B 812M 2025-12
Ultragenyx Pharmaceutical USD 321M 9.82M 2025-12
United Therapeutics USD 804.8M 5.79B 2025-12
Vertex Pharmaceuticals USD 1.93B 89.1M 2025-12